ERIN VILLELA: Open Payments
NPI 1942434360 · AUSTIN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,237 in 95 payments from 9 companies in 2025. Trend: 2023 $1,081 · 2024 $1,173 · 2025 $1,237
Food & beverage: $1,230Education: $7
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 22 | $281 |
| Amgen Inc. | 22 | $267 |
| Lilly USA, LLC | 16 | $165 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $164 |
| ABBVIE INC. | 12 | $163 |
| GlaxoSmithKline, LLC. | 3 | $68 |
| AstraZeneca Pharmaceuticals LP | 3 | $57 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $44 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $28 |
Products named: OTEZLA, TRINTELLIX, MOUNJARO, QULIPTA, Ozempic, TRELEGY ELLIPTA, Rybelsus, XIFAXAN.
Industry payments across TX — which companies pay providers there.
